A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
This trial is active, not recruiting.
|Conditions||chronic lymphocytic leukemia, non-hodgkin lymphoma|
|Sponsor||AbbVie (prior sponsor, Abbott)|
|Start date||June 2011|
|End date||January 2015|
|Trial size||211 participants|
|Trial identifier||NCT01328626, M12-175|
This is a Phase 1, open-label, multicenter study evaluating the safety and PK profile of ABT-199 under a once daily dosing schedule. Two arms will be implemented for dose escalation: Arm A, CLL/SLL subjects and Arm B, NHL subjects. Arm A is designed to enroll approximately 116 subjects with relapsed or refractory CLL or SLL and Arm B is designed to enroll approximately 95 subjects with relapsed or refractory NHL. Fifty-six subjects were enrolled in Arm A and approximately 55 subjects will be enrolled in Arm B during the dose escalation portion of the study, with the objective of defining dose limiting toxicities (DLTs) and the MTD. Once the MTD is declared for the arm, approximately 60 additional CLL/SLL subjects in Arm A and approximately 20 additional DLBCL subjects and 20 additional follicular lymphoma subjects in Arm B will be enrolled in an expanded safety portion of the study at the recommended phase 2 dose (RPTD) and schedule.
|United States||No locations recruiting|
|Other Countries||No locations recruiting|
|Tucson, AZ||The University of Arizona Medical Center-University Campus||no longer recruiting|
|La Jolla, CA||Site Reference ID/Investigator# 48325||no longer recruiting|
|San Diego, CA||University of California San Diego||no longer recruiting|
|Boston, MA||Dana-Farber Cancer Institute||no longer recruiting|
|Boston, MA||Site Reference ID/Investigator# 48324||no longer recruiting|
|New York, NY||Memorial Sloan-Kettering Cancer Center||no longer recruiting|
|Houston, TX||M D Anderson Cancer Center||no longer recruiting|
|Seattle, WA||Site Reference ID/Investigator# 135853||no longer recruiting|
|Seattle, WA||Fred Hutch / University of Washington Cancer Consortium||no longer recruiting|
|Madison, WI||Site Reference ID/Investigator# 56811||no longer recruiting|
|Madison, WI||University of Wisconsin Hospital and Clinics||no longer recruiting|
|East Melbourne, Australia||Site Reference ID/Investigator# 48323||no longer recruiting|
|Parkville, Melbourne, Australia||Site Reference ID/Investigator# 48322||no longer recruiting|
|Endpoint classification||safety study|
|Intervention model||parallel assignment|
Determination of dose limiting toxicity (DLT), maximum tolerated dose (MTD), recommended phase two dose (RPTD), and lead-in period regimen
time frame: Lead-in period (2-5 weeks) plus 3 weeks of study drug administration at the designated cohort dose (continuous dosing)
Determination of plasma peak concentration (Cmax), trough concentration (Ctrough), area under the concentration versus time curve (AUC) and urine recovery of ABT-199
time frame: Up to Week 24 for ABT-199
time frame: First 16 weeks of study drug administration and every 4 weeks thereafter (continuous dosing for an anticipated maximum duration of 9 months)
Preliminary efficacy assessment
time frame: Starting Week 4 for clinical disease progression and Week 6 for tumor response; and every 4 weeks thereafter (continuous dosing for an anticipated maximum duration of 9 months)
time frame: Week 1 Day -7 (single dose), Week 1 Day 1, and Week 6 Day 1
Biomarkers and pharmacogenetics
time frame: Screening, Week 1 Day 1, Week 6 Day 1, Week 24 Day 1, time of relapse and Final visit. Timepoints vary by disease type, assay performed and whether dose escalation or expanded safety portion of the study.
Minimal residual disease collection (MRD)
time frame: At least 2 months after the CR, CRi criteria for tumor response are first met. Every 12 weeks thereafter, until MRD negativity has been achieved (in peripheral blood).
Male or female participants from 18 years up to 99 years old.
Inclusion Criteria: - Subject must have either: - (Arm A) relapsed or refractory CLL/SLL and require treatment in the opinion of the Investigator. Subject must have relapsed following or be refractory to standard treatments such as fludarabine based regimens (F, FC, FR, FCR) or alkylator (chlorambucil, bendamustine) based regimens. In addition, there are no other curative options, and the subject has exhausted options that would be considered standard of care, or - (Arm B) relapsed or refractory NHL and require treatment in the opinion of the Investigator. Subject must have histologically documented diagnosis of NHL as defined in the World Health Organization classification scheme, except as noted in the exclusion criteria. Subject must have relapsed following or be refractory to standard treatments such as R-CHOP, R-CVP, or fludarabine based regimens. In addition, there are no other curative options, and the subject has exhausted options that would be considered standard of care. Subjects with other lymphoproliferative diseases can be considered in consultation with the Abbott medical monitor. - Subject has an Eastern Cooperative Oncology Group (ECOG) performance score less than or equal to 1. - Subject must have adequate bone marrow independent of growth factor support per local laboratory reference range at Screening. - Subject must have adequate coagulation, renal, and hepatic function, per laboratory reference range at Screening. Exclusion Criteria: - CLL subject has undergone an allogeneic or autologous stem cell transplant or NHL subject has undergone an allogeneic stem cell transplant or has been diagnosed with Post-Transplant Lymphoproliferative Disease, Burkitt's lymphoma, Burkitt-like lymphoma, or lymphoblastic lymphoma/leukemia. - Subject has tested positive for HIV. - Subject has a cardiovascular disability status of New York Heart Association Class greater or equal to 2. Class 2 is defined as cardiac disease in which patients are comfortable at rest but ordinary physical activity, results in fatigue, palpitations, dyspnea or anginal pain. - Subject has a significant history of renal, neurologic, psychiatric, pulmonary, endocrinologic, metabolic, immunologic, cardiovascular, or hepatic disease that in the opinion of the Investigator would adversely affect his/her participating in this study. - Subject has received a monoclonal antibody for anti-neoplastic intent within 8 weeks prior to the first dose of study drug.
|Official title||A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma|
|Description||Interventional Study Design - Primary Purpose: Determination of safety and tolerability.|
Call for more information